Alkermes

Source: news.yahoo.com --- 22 days ago
A drug to treat alcoholism developed by Alkermes Inc. has caused blood clots, swelling, abscesses, cell death and other adverse reactions in nearly 200 cases, according to a warning for health-care professionals issued Tuesday by the Food and Drug Administration. (ALKS) (CEPH) ...

Source: www.boston.com --- 30 days ago
A drug to treat alcoholism, manufactured by Alkermes Inc. has received marketing approval in Russia, the Cambridge-based company said today. Russian regulatory authorities approved the marketing of Vivitrol, a once-monthly, extended-release injectable medication for the treatment of alcohol dependence. The drug will be manufactured by Alkermes and commercialized by Janssen-Cilag, an affiliate company of Cilag GmbH International, a subsidiary of Johnson & Johnson. Approximately 10 million people in Russia are dependent on alcohol, according to a company release. In April 2006, the US Food and Drug Administration approved Vivitrol. In the US, the drug is commercialized mainly by Cephalon Inc. (By Elizabeth Campbell, Globe correspondent) ...

Source: www.marketwatch.com --- 27 days ago
Drug stocks move into positive territory as shares of Alkermes shoot up after it raises its fiscal 2009 financial outlook. ...

Source: www.marketwatch.com --- 25 days ago
BOSTON (MarketWatch) -- Drug stocks climbed into positive territory early Friday as shares of Alkermes Inc. jumped after it raised its fiscal 2009 financial outlook. The Amex Pharmaceutical Index inched up 0.4% to 312.9 and the Amex Biotechnology Index advanced 1% to 843.2. Alkermes shares shot up 9% to $15.79. ...

Source: www.medicalnewstoday.com --- 28 days ago
Alkermes, Inc. (NASDAQ: ALKS) announced that its partner, Cilag GmbH International, a subsidiary of Johnson & Johnson, received approval from the Russian Regulatory Authorities to market VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence in Russia. The product will be manufactured by Alkermes and commercialized by Janssen-Cilag, an affiliate company of Cilag GmbH International. ...

Source: www.medicalnewstoday.com --- 64 days ago
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 3 clinical trial of VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence. The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. The clinical data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S. ...

Source: www.medicalnewstoday.com --- 50 days ago
Alkermes, Inc. (NASDAQ: ALKS) announced positive preclinical results which demonstrated naltrexone for extended-release injectable suspension (XR-NTX) was more effective in an animal model of substance abuse compared to oral naltrexone therapy. The data were presented in an oral session at the 35th Annual Meeting and Exposition of the Controlled Release Society in New York City. ...

Source: seekingalpha.com --- 28 days ago
Alkermes, Inc (ALKS) F1Q09 (Qtr End 06/30/08) Earnings Call Transcript Complete Story » ...

Source: www.bloggingstocks.com --- 41 days ago
Filed under: Newsletters , Stocks to Buy " Alkermes (NASDAQ: ALKS ) recently produced a two-pronged positive surprise; an increase in the size of their already existing stock buyback program and a boost in their financial guidance," says John McCamant . In his Medical Technology Stock Letter , the biotech sector expert looks at this firm which focuses on treatments for central nervous system disorders, alcohol depenence, and schizophrenia. Here is his review. "Both of these moves were made possible by the announcement that ALKS has received a $40 million payment from Eli Lilly, their former partner for the now defunct AIR Insulin program. "ALKS now has the authorization to buy back up to $215 million in common stock. To date, the company has bought back roughly eight million shares of common stock for a cost of about $106 million. "Additionally, as noted, ALKS has upped their financial guidance for fiscal 2009. Operating income for the year is now expected to end up on the positive side of the ledger, with ALKS anticipating $10-$15 million for the full year. Continue reading Alkermes (ALKS): Buyback boosts biotech Permalink | Email this | Comments ...

Source: www.marketintelligencecenter.com --- 16 days ago
Alkermes (NasdaqNM: ALKS) opened at $14.71. So far today, the stock has hit a low of $14.20 and a high of $14.85. ALKS is now trading at $14.39, down $0.34 (-2.31%). Over the last 52 weeks the stock has ranged from a low of $10.32 to a high of $18.78. ALKS shares are declining today after Roth Capital cut its price target on the stock to $17 f... ...

Source: www.ad-hoc-news.de --- 16 days ago
Newport Beach (aktiencheck.de AG) - Die Analysten von Roth Capital stufen die Aktie von Alkermes (ISIN US01642T1088/ WKN 882907) unverändert mit hold ein. Das Kursziel werde von 18 auf 17 USD gesenkt. (19.08.2008/ac/a/u) ...

Source: www.topix.com --- 26 days ago
Drug stocks rallied Friday as shares of Alkermes Inc. shot up after it raised its fiscal 2009 financial outlook. ...

Source: www.topix.com --- 30 days ago
A drug manufactured by Alkermes Inc. to treat alcoholism has gained marketing approval in Russia. ...

Source: www.topix.com --- 21 days ago
A drug to treat alcoholism developed by Alkermes Inc. has caused blood clots, swelling, abscesses, cell death and other adverse reactions in nearly 200 cases, according to a warning for health care ... ...

Source: www.topix.com --- 41 days ago
Cambridge biotech firm Alkermes Inc. reports that its partner, Johnson & Johnson , has asked the U.S. Food and Drug Administration for approval of the two firms' drug, Risperdal/Consta, as a treatment for ... ...

Source: www.topix.com --- 49 days ago
Main Category: Schizophrenia Also Included In: Neurology / Neuroscience ; Clinical Trials / Drug Trials Article Date: 16 Jul 2008 - 4:00 PDT rate article Alkermes, Inc. ...

Source: medical-news-now.com --- 64 days ago
Alkermes Presents Positive Data on Proprietary Molecules Targeting …FOXBusiness - 26 minutes agoThe data were presented at the 2008 Research Society on Alcoholism/International Society for Biomedical Research on Alcoholism (RSA/ISBRA) Joint Scientific … ...

Source: migrainesadvice.com --- 35 days ago
Brain Injury Chronic Headache - Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 3 clinical trial of VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence. The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. ...

Source: au.rd.yahoo.com --- 23 days ago
WASHINGTON (Reuters) - Nearly 200 patients given Alkermes Inc's drug Vivitrol for alcohol dependence reported complications from the injection, including abscesses requiring surgical drainage, U.S. health regulators said on Tuesday. ...

Source: news.google.com --- 23 days ago
FDA warns of reactions to alcohol dependence drug Reuters - 2 hours ago By Susan Heavey WASHINGTON (Reuters) - Nearly 200 patients given Alkermes Inc's drug Vivitrol for alcohol dependence reported complications from the injection, including abscesses requiring surgical drainage, US health regulators said on Tuesday. FDA warns of skin reactions with alcoholism drug BusinessWeek FDA warns about Alkermes-Cephalon alcoholism drug Bizjournals.com Newsinferno.com  - Consumer Affairs  - U.S. News & World Report all 36 news articles ...